Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1625 1699
This examiner grants 67% of resolved cases
John D. McAnany has resolved 61 cases in Art Unit 1625. The data shows an allowance rate of 67.2% and a median days to allowance of 1221. This provides a baseline for prosecution in Tech Center 1600. The interview lift is 43.7%, which is a very high value that significantly improves the 67.2% baseline. This 43.7% lift suggests that interviews are a critical component of a successful strategy.
Practitioners should plan for a 1221-day median timeline. The 43.7% lift indicates that the examiner is highly responsive to direct communication. With 61 resolved cases, the 67.2% rate is a well-supported metric. The 1221-day median provides a realistic timeframe for applicants to reach a final resolution. In Art Unit 1625, the 67.2% allowance rate is a strong indicator of success.
In Tech Center 1600, the 1221-day median pendency is a key factor for planning. The 43.7% interview lift is one of the most impactful metrics in this profile. Applicants should prioritize interviews to navigate the 1221-day process effectively. The 61 cases on record provide a clear picture of the examiner's responsiveness to verbal advocacy.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17271981 | METHODS OF DETERMINING TREATMENT CONSISTING OF RADIATION THERAPY AND/OR ALKYLATING CHEMOTHERAPY IN PATIENTS SUFFERING FROM CANCER | Final Rejection | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH |
| 18572447 | INDOCARBOCYANINE LIPID DERIVATIVES FOR IN VIVO CARGO DELIVERY | Final Rejection | NORTHWESTERN UNIVERSITY |
| 18547462 | 2-SUBSTITUTED BICYCLO[1.1.1]PENTANES | Non-Final OA | The Trustees of Princeton University |
| 18826792 | COMPOSITIONS AND METHODS FOR ENHANCING KRAS INHIBITOR OR SHP2 INHIBITOR EFFICACY | Non-Final OA | New York University |
| 18037751 | INHIBITORS OF IGF2BP1-RNA BINDING | Final Rejection | THE PENN STATE RESEARCH FOUNDATION |
| 18784840 | PROANGIOGENIC PROTEIN COCKTAILS DELIVERED IN CUSTOM BIOMATERIALS TO REVASCULARIZE ISCHEMIC TISSUE | Non-Final OA | Brown University |
| 18852916 | TRANS-VACCENIC ACID (TVA) AND DERIVATIVES THEREOF IN T CELL-BASED CANCER THERAPIES | Non-Final OA | The University of Chicago |
| 18048731 | DUAL HDAC6/PROTEASOME INHIBITORS, AND METHODS OF USE THEREOF | Non-Final OA | UNIVERSITY OF MARYLAND, BALTIMORE |
| 18549412 | METHOD FOR PREPARING AMIDINES | Final Rejection | VERSALIS S.P.A. |
| 17430210 | METHODS FOR TREATING CHOLESTASIS | Final Rejection | MIRUM PHARMACEUTICALS, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy